JMP Securities Downgrades Syros Pharmaceuticals (SYRS) to Market Perform
Tweet
Share
E-mailGet Alerts SYRS Hot Sheet
Price: $0.12 --0%
Rating Summary:
4 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
4 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
JMP Securities downgraded Syros Pharmaceuticals (NASDAQ: SYRS) from Market Outperform to Market Perform.
Analyst Michael King Jr. cites the valuation for his downgrade noting the stock is trading above his $22.00 price target. The analyst comments that over the LT investors "will be amply rewarded" for retaining faith in the company's technology platform and management team.
For an analyst ratings summary and ratings history on Syros Pharmaceuticals click here. For more ratings news on Syros Pharmaceuticals click here.
Shares of Syros Pharmaceuticals closed at $22.84 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades LENZ Therapeutics Inc (LENZ) to Neutral
- BofA Securities Downgrades Bending Spoons (BSP) to Underperform
- Riskified Ltd. (RSKD) PT Raised to $5.50 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst Comments, DowngradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
